Featured Articles
-
What Happens When Acquisition Due Diligence Ignores Clinical Operations?
11/16/2026
An acquisition’s hidden costs can emerge at clinical trial sites. Here’s why leadership needs to consider clinical operations in due diligence.
-
Communicate Change With AI, Not As AI
11/13/2026
AI can support the thinking, the planning, and the rehearsal. But company leaders communicating change should sound like themselves, not AI, writes Maria Bostock FCIPD.
-
The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
11/9/2026
A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.
-
Five Lessons For Biotech CEOs Pioneering A New Therapeutic Modality
11/5/2026
Scientific conviction, resilience, and clinical evidence can turn early skepticism into meaningful progress for patients, writes RiboX Therapeutics' Weiyi Zhang, Ph.D.
-
After Hikma: A Transatlantic View Of Skinny Labels And Pharma Strategy
11/3/2026
The Hikma ruling clarifies U.S. skinny-label protections, but divergent European rules complicate patent, launch, and litigation strategies, according to legal experts.
-
Why Pharma Needs More Physicians And How To Get There
10/30/2026
Physicians can broaden their patient impact in pharma, but they need better exposure to industry career paths, writes physician-scientist Emmanuelle Clerisme-Beaty, M.D.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
10/28/2026
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
-
An Express Lane To Clinical Testing? FDA's Expedited IND Pilot Program
10/27/2026
FDA’s Expedited IND pilot pairs developers with expert advisers and uses rolling submissions to improve IND quality and accelerate Phase 1 trials, writes Luke Nguyen.
-
MFN Cuts Manufacturer Prices, But Savings Still Face A Longer Journey
10/23/2026
MFN cuts manufacturer drug prices, but transparency across PBMs and pharmacies is needed to ensure the savings reach patients, writes Paul Pruitt.
-
A 250 Million Patient Blind Spot: Why Pharma Ignored Lymphatic Medicine
10/21/2026
Once overlooked as the merely the human body’s plumbing, the lymphatic system is emerging as a new therapeutic frontier, writes Celltaxis CEO Eileen Heffernan.